Improving the rate of patient response to immune checkpoint blockade therapy is a current clinical goal. An article published in Science suggests that some members of the gut microbiome may provide a key molecule toward this end.
from Cancer Cell https://ift.tt/2RUvMzT
from Cancer Cell https://ift.tt/2RUvMzT